FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Andrew Zhu

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Antineoplastic Combined Chemotherapy Protocols

Co-author Network

Publications

TOP 3
Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma.
Andrew X Zhu; Thomas A Abrams; Marek Ancukiewicz; Pankaj Bhargava; Lawrence S Blaszkowsky; Charles S Fuchs; Rakesh K Jain; Michelle Knowles; Nadine Jackson McCleary; Jeffrey A Meyerhardt; Alona Muzikansky; Eileen Regan; David P Ryan; Dushyant V Sahani; Susan Sheehan; Jeffrey G Supko; Eamala Vasudev; Dan G Duda
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Andrew X Zhu; Thomas A Abrams; Anthony B El-Khoueiry; Philip J Gold; Hideo Morikawa; Norihisa Ohishi; Toshihiko Ohtomo; Philip A Philip
First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Andrew Zhu (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Lipika Goyal; Mandar D Muzumdar; Andrew X Zhu
Targeting the HGF/c-MET Pathway in Hepatocellular Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(9):2310-8.
2013: Andrew X Zhu; Thomas A Abrams; Marek Ancukiewicz; Pankaj Bhargava; Lawrence S Blaszkowsky; Charles S Fuchs; Rakesh K Jain; Michelle Knowles; Nadine Jackson McCleary; Jeffrey A Meyerhardt; Alona Muzikansky; Eileen Regan; David P Ryan; Dushyant V Sahani; Susan Sheehan; Jeffrey G Supko; Eamala Vasudev; Dan G Duda
Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(6):1557-66.
2013: Andrew X Zhu; Thomas A Abrams; Anthony B El-Khoueiry; Philip J Gold; Hideo Morikawa; Norihisa Ohishi; Toshihiko Ohtomo; Philip A Philip
First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(4):920-8.
2013: Sanjeeva Kalva; Melina Pectasides; Kalpana Yeddula; Lawrence S Blaszkowsky; Suvranu Ganguli; Andrew X Zhu
Factors affecting survival following chemoembolization with doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.
Journal of vascular and interventional radiology : JVIR 2013;24(2):257-65.
2013: Andrew X Zhu; Riad Salem
Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: one step forward?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(4):406-8.
2013: Brian M Wolpin; Andrew X Zhu; Thomas Abrams; Jill N Allen; Pankaj Bhargava; Lawrence S Blaszkowsky; Jennifer A Chan; Meaghan Elliot; Peter C Enzinger; Wolfram Goessling; Eunice L Kwak; Nadine J McCleary; Jeffrey A Meyerhardt; Kimmie Ng; Eileen Regan; Kaori Sato; Deborah Schrag; Jeffrey G Supko; Charles S Fuchs
Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer.
The oncologist 2013;18(4):377-8.
2013: Andrew X Zhu
New agents on the horizon in hepatocellular carcinoma.
Therapeutic advances in medical oncology 2013;5(1):41-50.
2013: Tao Jiang; Andrew X Zhu; Dushyant V Sahani
Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.
Journal of hepatology 2013;58(1):169-77.
2012: Jennifer A Chan; Charles S Fuchs; Thomas A Abrams; Paige Malinowski; Eileen M Regan; David P Ryan; Brian M Wolpin; Andrew X Zhu; Matthew H Kulke
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors.
Endocrine-related cancer 2012;19(5):615-23.
2012: Andrew X Zhu
Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
Clinical drug investigation 2012;32 Suppl 2():1-2.
2012: Andrew X Zhu
Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives.
Seminars in oncology 2012;39(4):493-502.
2012: Nils D Arvold; Lawrence S Blaszkowsky; Jeffrey W Clark; Vikram Deshpande; Carlos Fernandez-Del Castillo; Cristina R Ferrone; Eunice L Kwak; Andrzej Niemierko; David P Ryan; Raymond C Wadlow; Andrew L Warshaw; Christopher G Willett; Andrew X Zhu; Jill N Allen; Theodore S Hong
Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
International journal of radiation oncology, biology, physics 2012;83(3):e337-43.
2012: Jason E Faris; Andrew X Zhu
Targeted therapy for biliary tract cancers.
Journal of hepato-biliary-pancreatic sciences 2012;19(4):326-36.
2012: Nils D Arvold; Lawrence S Blaszkowsky; Jeffrey W Clark; Carlos Fernandez-Del Castillo; Eunice L Kwak; Andrzej Niemierko; David P Ryan; Raymond C Wadlow; Jennifer Y Wo; Andrew X Zhu; Jill N Allen; Theodore S Hong
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.
Cancer 2012;118(12):3026-35.
2012: Darrell R Borger; Andrew X Zhu
IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
Expert review of anticancer therapy 2012;12(5):543-6.
2012: Michael R O'Dell; Randall M Rossi; Paul Rothberg; Christa L Whitney-Miller; Andrew X Zhu; Jing Li Huang; Nabeel Bardeesy; Vikram Deshpande; Valerie Grose; Hartmut Land; Aram F Hezel
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.
Cancer research 2012;72(6):1557-67.
2012: Andrew X Zhu; Jennifer J Knox
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
The oncologist 2012;17(12):1504-7.
2012: Jeffrey A Meyerhardt; Eileen Regan; Deborah Schrag; Brian M Wolpin; Andrew X Zhu; Thomas A Abrams; Marek Ancukiewicz; Lawrence S Blaszkowsky; Jennifer A Chan; Meaghan Elliott; Peter C Enzinger; Michael Goldstein; Rakesh K Jain; Matthew H Kulke; Dan G Duda
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
PloS one 2012;7(6):e38231.
2012: Raymond C Wadlow; Brian M Wolpin; Andrew X Zhu; Thomas A Abrams; Lawrence S Blaszkowsky; Charles S Fuchs; Aram F Hezel; Matthew H Kulke; Eunice L Kwak; Jeffrey A Meyerhardt; David P Ryan; Jackie Szymonifka; Jeffrey W Clark
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
The oncologist 2012;17(1):14.
2012: Darrell R Borger; Jeffrey W Clark; Vikram Deshpande; Dora Dias-Santagata; Leif W Ellisen; Kenneth C Fan; Valeria R Fantin; Aram F Hezel; Eunice L Kwak; Hannah M Liebman; Hector U Lopez; David P Ryan; David P Schenkein; Kimberly S Straley; Kenneth K Tanabe; Andrew X Zhu; Marek Ancukiewicz; A John Iafrate
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
The oncologist 2012;17(1):72-9.
2011: Andrew X Zhu; Deborah Schrag; Hui Zheng; Thomas A Abrams; Lawrence S Blaszkowsky; Darrell R Borger; Jeffrey W Clark; Charles S Fuchs; A John Iafrate; Kathryn R Jors; Eunice L Kwak; Jeffrey A Meyerhardt; Rebecca Miksad; Alona Muzikansky; David P Ryan
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma.
Cancer 2011;117(22):5094-102.
2011: Mechteld C de Jong; Cristina R Ferrone; T Clark Gamblin; Jean-Francois Gigot; Catherine Hubert; Hugo Marques; Gilles Mentha; Stephanie Meyer; Hari Nathan; Kevin T Nguyen; Andreas Paul; Luca Aldrighetti; Sorin Alexandrescu; Eduardo Barroso; Todd W Bauer; Michael A Choti; Bryan M Clary; Irinel Popescu; Carlo Pulitano; Richard D Schulick; Georgios C Sotiropoulos; Ryan Turley; Dustin M Walters; Andrew X Zhu; Timothy M Pawlik
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(23):3140-5.
2011: Matthew H Kulke; Jeffrey A Meyerhardt; Eileen Regan; Carolyn Sidor; Andrew X Zhu; Thomas A Abrams; Lawrence S Blaszkowsky; Jennifer A Chan; Charles S Fuchs
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors.
Cancer chemotherapy and pharmacology 2011;68(2):293-300.
2011: J A Chan; Lawrence S Blaszkowsky; Peter C Enzinger; David P Ryan; Thomas A Abrams; Andrew X Zhu; Jennifer S Temel; D Schrag; Pankaj Bhargava; Jeffrey A Meyerhardt; Brian M Wolpin; Panos Fidias; H Zheng; S Florio; E Regan; Charlie S Fuchs
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(6):1367-73.
2011: Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
HCC and angiogenesis: possible targets and future directions.
Nature reviews. Clinical oncology 2011;8(5):292-301.
2011: Andrew X Zhu; Dan G Duda; Marek Ancukiewicz; Emmanuelle di Tomaso; Jeffrey W Clark; Rebecca Miksad; Charles S Fuchs; David P Ryan; Rakesh K Jain
Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(4):918-27.
2011: Andrew X Zhu; Aram F Hezel
Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.
Hepatology (Baltimore, Md.) 2011;53(2):695-704.
2011: Ann-Lii Cheng; Ying-Chun Shen; Andrew X Zhu
Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma.
Oncology 2011;81(5-6):372-80.
2011: Jennifer Wu; Andrew X Zhu
Targeting insulin-like growth factor axis in hepatocellular carcinoma.
Journal of hematology & oncology 2011;4():30.
2011: Sanjeeva Kalva; Shams I Iqbal; Kalpana Yeddula; Lawrence S Blaszkowsky; Adnan Akbar; Stephan Wicky; Andrew X Zhu
Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.
Gastrointestinal cancer research : GCR 2011;4(1):2-8.
2011: Olga N Kozyreva; Dorcas Chi; Jeffrey W Clark; Hejing Wang; Kathy P Theall; David P Ryan; Andrew X Zhu
A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma.
The oncologist 2011;16(3):310-8.
2011: Vikram Deshpande; Afamefuna Nduaguba; Stephanie M Zimmerman; Sarah M Kehoe; Laura E Macconaill; Gregory Y Lauwers; Cristina Ferrone; Nabeel Bardeesy; Andrew X Zhu; Aram F Hezel
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.
BMC cancer 2011;11():60.
2010: Jennifer A Chan; Andrew X Zhu; Keith Stuart; Pankaj Bhargava; Craig C Earle; Jeffrey W Clark; Carolyn Casey; Eileen Regan; Matthew H Kulke
Phase II study of pemetrexed in patients with advanced neuroendocrine tumors.
Cancer chemotherapy and pharmacology 2010;66(5):961-8.
2010: Jennifer Wu; Charles Henderson; Lynn Feun; Peter Van Veldhuizen; Philip Gold; Hui Zheng; Theresa Ryan; Lawrence S Blaszkowsky; Haobin Chen; Max Costa; Barry Rosenzweig; MaryLynn Nierodzik; Howard Hochster; Franco Muggia; Giovanni Abbadessa; Jonathan Lewis; Andrew X Zhu
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
Investigational new drugs 2010;28(5):670-6.
2010: George A. Poultsides; Andrew X Zhu; Michael A Choti; Timothy M Pawlik
Intrahepatic cholangiocarcinoma.
The Surgical clinics of North America 2010;90(4):817-37.
2010: Aram F Hezel; Vikram Deshpande; Andrew X Zhu
Genetics of biliary tract cancers and emerging targeted therapies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(21):3531-40.
2010: Joseph Paul Eder; Geoffrey I Shapiro; Leonard J Appleman; Andrew X Zhu; Dale Miles; Harold Keer; Belinda Cancilla; Felix Chu; Suzanne Hitchcock-Bryan; Laurie Sherman; Stewart McCallum; Elisabeth Iljas Heath; Scott A Boerner; Patricia M LoRusso
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(13):3507-16.
2010: Kelly W Burak; Melanie B Thomas; Andrew X Zhu
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
HPB : the official journal of the International Hepato Pancreato Biliary Association 2010;12(5):321-2.
2010: Andrew X Zhu
Systemic treatment of hepatocellular carcinoma: dawn of a new era?
Annals of surgical oncology 2010;17(5):1247-56.
2010: Andrew X Zhu
Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Expert opinion on investigational drugs 2010;19(5):663-72.
2010: Laura Rubbia-Brandt; Gregory Y Lauwers; Huamin Wang; Pietro E Majno; Kenneth Tanabe; Andrew X Zhu; Catherine Brezault; Olivier Soubrane; Eddie K Abdalla; Jean-Nicolas Vauthey; Gilles Mentha; Benoit Terris
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis.
Histopathology 2010;56(4):430-9.
2010: Andrew X Zhu; Bruce A Chabner; Kenneth K Tanabe
New trends and novel treatment for hepatocellular carcinoma: a global perspective.
The oncologist 2010;15 Suppl 4():1-4.
2010: Andrew X Zhu; Theodore S Hong; Aram F Hezel; David A Kooby
Current management of gallbladder carcinoma.
The oncologist 2010;15(2):168-81.
2010: Andrew X Zhu; Jeffrey A Meyerhardt; Lawrence S Blaszkowsky; Avinash R Kambadakone; Alona Muzikansky; Hui Zheng; Jeffrey W Clark; Thomas A Abrams; Jennifer A Chan; Peter C Enzinger; Pankaj Bhargava; Eunice L Kwak; Jill N Allen; Sanjay R Jain; Keith Stuart; Kerry Horgan; Susan Sheehan; Charles S Fuchs; David P Ryan; Dushyant V Sahani
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
The lancet oncology 2010;11(1):48-54.
2009: Abby B Siegel; Andrew X Zhu
Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link.
Cancer 2009;115(24):5651-61.
2009: James M Cleary; Kenneth T Tanabe; Gregory Y Lauwers; Andrew X Zhu
Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.
The oncologist 2009;14(11):1095-105.
2009: Andrew X Zhu; Anthony El-Khoueiry; Josep M Llovet
Accomplishments in 2008 in the management of hepatobiliary cancers.
Gastrointestinal cancer research : GCR 2009;3(5 Supplement 2):S28-36.
2009: Andrew X Zhu; Dan G Duda; Dushyant V Sahani; Rakesh K Jain
Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies.
Cancer journal (Sudbury, Mass.) 2009;15(4):263-8.
2009: Sadhna R Vora; Hui Zheng; Zsofia Kinga Stadler; Charles S Fuchs; Andrew X Zhu
Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
The oncologist 2009;14(7):717-25.
2009: Andrew X Zhu; Dushyant V Sahani; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Onofrio A Catalano; Vivek Sindhwani; Lawrence S Blaszkowsky; Sam S Yoon; Johanna Lahdenranta; Pankaj Bhargava; Jeffrey A Meyerhardt; Jeffrey W Clark; Eunice L Kwak; Aram F Hezel; Rebecca Miksad; Thomas A Abrams; Peter C Enzinger; Charlie S Fuchs; David P Ryan; Rakesh K Jain
Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(18):3027-35.
2009: Rakesh K Jain; Dan G Duda; Christopher G Willett; Dushyant V Sahani; Andrew X Zhu; Jay S Loeffler; Tracy T Batchelor; A Gregory Sorensen
Biomarkers of response and resistance to antiangiogenic therapy.
Nature reviews. Clinical oncology 2009;6(6):327-38.
2009: Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge A Marrero; Steven G Meranze; Sean J Mulvihill; James Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos T Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(4):350-91.
2009: Richard S Finn; Andrew X Zhu
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Expert review of anticancer therapy 2009;9(4):503-9.
2009: Peter C Enzinger; David P Ryan; jeffrey clark; Alona Muzikansky; Craig C Earle; Matthew H Kulke; Jeffrey A Meyerhardt; Lawrence S Blaszkowsky; Andrew X Zhu; Panos Fidias; Michele Vincitore; Robert J Mayer; Charlie S Fuchs
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(3):475-80.
2009: Adam D Lipworth; Caroline Robert; Andrew X Zhu
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Oncology 2009;77(5):257-71.
2009: Rebecca A Miksad; Kuan-Chi Lai; Marion C Stein; Megan E Healy; Rafael Rojas; Katherine M Krajewski; Andrew X Zhu
Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer.
Journal of gastrointestinal cancer 2009;40(3-4):119-22.
2009: Andrew X Zhu
Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?
BMC medicine 2009;7():42.
2009: Bernardo H L Goulart; Jeffrey W Clark; Gregory Y Lauwers; David P Ryan; Nina Grenon; Alona Muzikansky; Andrew X Zhu
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
Journal of hematology & oncology 2009;2():13.
2009: Andrew X Zhu; jeffrey clark
Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
The oncologist 2009;14(1):67-9.
2009: Andrew X Zhu; Neal Ready; jeffrey clark; Howard Safran; Antonino Amato; Nadia Salem; Silvia Pace; Xiaoying He; Nela Zvereva; Thomas J Lynch; David P Ryan; Jeffrey G Supko
Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):374-81.
2009: Andrew X Zhu; Eric Raymond
Early development of sunitinib in hepatocellular carcinoma.
Expert review of anticancer therapy 2009;9(1):143-50.
2009: Hari Nathan; Thomas A Aloia; Jean-Nicolas Vauthey; Eddie K Abdalla; Andrew X Zhu; Richard D Schulick; Michael A Choti; Timothy M Pawlik
A proposed staging system for intrahepatic cholangiocarcinoma.
Annals of surgical oncology 2009;16(1):14-22.
2008: Nisha I Sainani; Onofrio A Catalano; Nagaraj Holalkere; Andrew X Zhu; Peter F Hahn; Dushyant V Sahani
Cholangiocarcinoma: current and novel imaging techniques.
Radiographics : a review publication of the Radiological Society of North America, Inc 2008;28(5):1263-87.
2008: Kofi Asomaning; Amy E Reid; Wei Zhou; C. Rebecca Suk Heist; Rihong Zhai; Li Su; Eunice L Kwak; Lawrence Blaszkowsky; Andrew X Zhu; David P Ryan; David C Christiani; Geoffrey Liu
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):4010-5.
2008: Josep M Llovet; Adrian M Di Bisceglie; Jordi Bruix; Barnett S Kramer; Riccardo Lencioni; Andrew X Zhu; Morris Sherman; Myron Schwartz; Michael Lotze; Jayant Talwalkar; Gregory J Gores
Design and endpoints of clinical trials in hepatocellular carcinoma.
Journal of the National Cancer Institute 2008;100(10):698-711.
2008: Andrew X Zhu; Ghassan K Abou-Alfa
Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation.
JAMA : the journal of the American Medical Association 2008;299(14):1716-8.
2008: Aram F Hezel; Andrew X Zhu
Systemic therapy for biliary tract cancers.
The oncologist 2008;13(4):415-23.
2008: Andrew X Zhu
Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
Expert review of anticancer therapy 2008;8(4):499-505.
2008: Bryan C Fuchs; Tsutomu Fujii; Jon D Dorfman; Jonathan M Goodwin; Andrew X Zhu; Michael Lanuti; Kenneth K Tanabe
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
Cancer research 2008;68(7):2391-9.
2008: Andrew X Zhu; Nagaraj Holalkere; Alona Muzikansky; Kerry Horgan; Dushyant V Sahani
Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma.
The oncologist 2008;13(2):120-5.
2008: Jeffrey A Meyerhardt; Andrew X Zhu; Keith Stuart; David P Ryan; Lawrence S Blaszkowsky; Nicole Lehman; Craig C Earle; Matthew H Kulke; Pankaj Bhargava; Charlie S Fuchs
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
Digestive diseases and sciences 2008;53(2):564-70.
2008: Andrew X Zhu
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Cancer 2008;112(2):250-9.
2008: Kimmie Ng; Andrew X Zhu
Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
Critical reviews in oncology/hematology 2008;65(1):8-20.
2007: Matthew H Kulke; Lawrence S Blaszkowsky; David P Ryan; jeffrey clark; Jeffrey A Meyerhardt; Andrew X Zhu; Peter C Enzinger; Eunice L Kwak; Alona Muzikansky; Colleen Lawrence; Charlie S Fuchs
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4787-92.
2007: Jeffrey A Meyerhardt; jeffrey clark; Jeffrey G Supko; Joseph P Eder; Shuji Ogino; Clinton F Stewart; Ferdinando D'Amato; Janet Dancey; Peter C Enzinger; Andrew X Zhu; David P Ryan; Craig C Earle; Robert J Mayer; Ann Michelini; Kate Kinsella; Charlie S Fuchs
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Cancer chemotherapy and pharmacology 2007;60(5):661-70.
2007: Andrew X Zhu; Keith Stuart; Lawrence S Blaszkowsky; Alona Muzikansky; Donald P Reitberg; jeffrey clark; Peter C Enzinger; Pankaj Bhargava; Jeffrey A Meyerhardt; Kerry Horgan; Charlie S Fuchs; David P Ryan
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
Cancer 2007;110(3):581-9.
2007: Jeffrey A Meyerhardt; Keith Stuart; Charlie S Fuchs; Andrew X Zhu; Craig C Earle; Pankaj Bhargava; Lawrence S Blaszkowsky; Peter C Enzinger; Robert J Mayer; S Battu; C Lawrence; David P Ryan
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(7):1185-9.
2007: A Craig Lockhart; R Bukowski; Mace L Rothenberg; K K Wang; W Cooper; J Grover; Leonard J Appleman; P R Mayer; M Shapiro; Andrew X Zhu
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Cancer chemotherapy and pharmacology 2007;60(2):203-9.
2007: Dushyant V Sahani; Nagaraj Holalkere; Peter R Mueller; Andrew X Zhu
Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience.
Radiology 2007;243(3):736-43.
2007: Andrew X Zhu; jeffrey clark; David P Ryan; Jeffrey A Meyerhardt; Peter C Enzinger; Craig C Earle; Charlie S Fuchs; Eileen Regan; Hiroshi Anbe; Michele Houghton; Joshua Zhang; Peter Urrea; Matthew H Kulke
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Cancer chemotherapy and pharmacology 2007;59(3):285-93.
2006: Heather Mernitz; Donald E Smith; Andrew X Zhu; Xiang Wang
9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2.
Cancer letters 2006;244(1):101-8.
2006: David P Ryan; Leonard J Appleman; Thomas J Lynch; Jeffrey G Supko; Panos Fidias; jeffrey clark; Mayer Fishman; Andrew X Zhu; Peter C Enzinger; Oscar Kashala; James C Cusack; Joseph P Eder
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Cancer 2006;107(10):2482-9.
2006: Brian M Wolpin; jeffrey clark; Jeffrey A Meyerhardt; Craig C Earle; David P Ryan; Peter C Enzinger; Andrew X Zhu; Lawrence S Blaszkowsky; Subha Battu; Charlie S Fuchs
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
Clinical colorectal cancer 2006;6(3):208-13.
2006: Matthew H Kulke; Emily K Bergsland; David P Ryan; Peter C Enzinger; Thomas J Lynch; Andrew X Zhu; Jeffrey A Meyerhardt; John V Heymach; William E Fogler; Carolyn Sidor; Ann Michelini; Kate Kinsella; Alan P Venook; Charlie S Fuchs
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3555-61.
2006: Andrew X Zhu
Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?
The oncologist 2006;11(7):790-800.
2006: Joseph P Eder; David P Ryan; Leonard J Appleman; Andrew X Zhu; Thomas A Puchalski; Xiaoying He; Daryl S Sonnichsen; Michael Cooper; John Wright; jeffrey clark; Jeffrey G Supko
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2006;58(1):107-16.
2006: Matthew H Kulke; Bingyan Wu; David P Ryan; Peter C Enzinger; Andrew X Zhu; jeffrey clark; Craig C Earle; Ann Michelini; Charlie S Fuchs
A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.
Digestive diseases and sciences 2006;51(6):1033-8.
2006: Jeffrey A Meyerhardt; Denise Heseltine; Shuji Ogino; jeffrey clark; Peter C Enzinger; David P Ryan; Craig C Earle; Andrew X Zhu; Charlie S Fuchs
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
Clinical colorectal cancer 2006;6(1):59-65.
2006: Andrew X Zhu; Alan D D'Andrea; Dushyant V Sahani; Robert P Hasserjian
Case records of the Massachusetts General Hospital. Case 13-2006. A 50-year-old man with a painful bone mass and lesions in the liver.
The New England journal of medicine 2006;354(17):1828-37.
2006: Andrew X Zhu; Lawrence S Blaszkowsky; David P Ryan; jeffrey clark; Alona Muzikansky; Kerry Horgan; Susan Sheehan; Kelly E Hale; Peter C Enzinger; Pankaj Bhargava; Keith Stuart
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1898-903.
2006: Jeffrey A Meyerhardt; Andrew X Zhu; Peter C Enzinger; David P Ryan; jeffrey clark; Matthew H Kulke; Craig C Earle; Michele Vincitore; Ann Michelini; Susan Sheehan; Charlie S Fuchs
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1892-7.
2005: Christopher G Willett; Yves Boucher; Dan G Duda; Emmanuelle di Tomaso; Lance L Munn; Ricky T Tong; Sergey V Kozin; Lucine Petit; Rakesh K Jain; Daniel C Chung; Dushyant V Sahani; Sanjeeva Kalva; Kenneth S Cohen; David T Scadden; Alan J Fischman; jeffrey clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Paul C Shellito; Mari Mino-Kenudson; Gregory Y Lauwers
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):8136-9.
2005: Andrew X Zhu; Charlie S Fuchs; jeffrey clark; Alona Muzikansky; Kerry Taylor; Susan Sheehan; Kayao Tam; Elizabeth Yung; Matthew H Kulke; David P Ryan
A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
The oncologist 2005;10(6):392-8.
2005: Melanie Thomas; Andrew X Zhu
Hepatocellular carcinoma: the need for progress.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2892-9.
2005: Eric L Krakauer; Andrew X Zhu; Brenna C Bounds; Dushyant V Sahani; Kevin R McDonald; Elena F Brachtel
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2005. A 58-year-old man with esophageal cancer and nausea, vomiting, and intractable hiccups.
The New England journal of medicine 2005;352(8):817-25.
2005: Andrew X Zhu; Christopher G Willett
Combined modality treatment for rectal cancer.
Seminars in oncology 2005;32(1):103-12.
2005: Christopher G Willett; Carlos Fernandez Del Castillo; Helen A Shih; Saveli Goldberg; Peter Biggs; jeffrey clark; Gregory Y Lauwers; David P Ryan; Andrew X Zhu; Andrew L Warshaw
Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer.
Annals of surgery 2005;241(2):295-9.
2005: Jennifer F Tseng; Christopher G Willett; Carlos Fernandez-Del Castillo; David P Ryan; jeffrey clark; Andrew X Zhu; David W Rattner; Jennifer L Winkelmann; Andrew L Warshaw
Patients undergoing treatment for pancreatic adenocarcinoma can mount an effective immune response to vaccinations.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2005;5(1):67-74.
2004: Jessica Y Leung; Andrew X Zhu; Fredric D Gordon; Daniel S Pratt; Abigail Mithoefer; Kathryn Garrigan; Adam Terella; Martin Hertl; A Benedict Cosimi; Raymond T Chung
Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2004;10(11):1343-54.
2004: Andrew X Zhu; jeffrey clark; Christopher G Willett
Adjuvant therapy for pancreatic cancer: an evolving paradigm.
Surgical oncology clinics of North America 2004;13(4):605-20, viii.
2004: Benjamin D Humphreys; Jeff P Sharman; Joel M Henderson; jeffrey clark; Peter W Marks; Helmut G Rennke; Andrew X Zhu; Colm C Magee
Gemcitabine-associated thrombotic microangiopathy.
Cancer 2004;100(12):2664-70.
2004: Andrew X Zhu; Thomas A Puchalski; Vincent P Stanton; David P Ryan; jeffrey clark; Steven Nesbitt; Olga Charlat; Patrick Kelly; Elaine Kreconus; Bruce A Chabner; Jeffrey G Supko
Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Clinical colorectal cancer 2004;3(4):225-34.
2004: Christopher G Willett; Yves Boucher; Emmanuelle di Tomaso; Dan G Duda; Lance L Munn; Ricky T Tong; Daniel C Chung; Dushyant V Sahani; Sanjeeva Kalva; Sergey V Kozin; Mari Mino; Kenneth S Cohen; David T Scadden; Alan C Hartford; Alan J Fischman; jeffrey clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Helen X Chen; Paul C Shellito; Gregory Y Lauwers; Rakesh K Jain
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
Nature medicine 2004;10(2):145-7.
2004: Andrew X Zhu; Gregory Y Lauwers; Kenneth K Tanabe
Cholangiocarcinoma in association with Thorotrast exposure.
Journal of hepato-biliary-pancreatic surgery 2004;11(6):430-3.
2003: Andrew X Zhu; Christopher G Willett
Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.
Seminars in radiation oncology 2003;13(4):454-68.
2003: Andrew X Zhu; Raymond T Chung
Hepatic steatosis in patients with chronic hepatitis C virus infection. Another risk factor for hepatocellular carcinoma?
Cancer 2003;97(12):2948-50.
2003: Andrew X Zhu
Hepatocellular carcinoma: are we making progress?
Cancer investigation 2003;21(3):418-28.
2003: W Kevin Kelly; Andrew X Zhu; Howard I Scher; Tracy Curley; Mary Fallon; Susan F Slovin; Lawrence H Schwartz; Steven M Larson; William Tong; Beryl Hartley-Asp; Cinzia Pellizzoni; Maurizio Rocchetti
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):2098-107.